TATE-DA-I
TATE-DA-I is a somatostatin receptor 2 (SSTR2) ligand with an IC50 of 25.3 nM. TATE-DA-I binds to albumin to prolong its circulation retention time and also exhibits enhanced tumor accumulation capacity. TATE-DA-I enables clear visualization of SSTR2-positive tumors in SPECT/CT imaging. TATE-DA-I can be used in cancer-related research.
For research use only. We do not sell to patients.
- Formula: C87H119IN16O25S2
- Molecular Weight:1980.00
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
|
SSTR2 25.3 nM (IC50) |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| AR-42J cell line | IC50 |
25.3 nM
|
Inhibition of [111In]In-DOTA-TATE binding to SSTR2 on AR42J rat pancreatic exocrine adenocarcinoma cells by metal-free TATE-DA-I, assessed via radioactivity measurement after 2 h incubation at 37 °C.
Inhibition of [111In]In-DOTA-TATE binding to SSTR2 on AR42J rat pancreatic exocrine adenocarcinoma cells by metal-free TATE-DA-I, assessed via radioactivity measurement after 2 h incubation at 37 °C.
|
41710742 |
TATE-DA-I inhibits SSTR2 binding on AR42J cells with an IC50 of 25.3 nM, and its potency is significantly lower than that of DOTA-TATE (HY-106244)[1].
TATE-DA-I radiolabeled derivative [111In]In-TATE-DA-I shows high in vitro stability in mouse plasma and human plasma after incubation at 37 °C for 24 h[1].[1].
TATE-DA-I radiolabeled derivative [111In]In-TATE-DA-I specifically binds to somatostatin receptor 2 (SSTR2) on AR42J cells[1].
TATE-DA-I radiolabeled derivative [111In]In-TATE-DA-I displays the highest relative binding activity to human serum albumin among all tested radioligands, and its binding rate rises as HSA concentration increases[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
TATE-DA-I radiolabeled derivative [111In]In-TATE-DA-I (37 kBq; single intravenous injection) specifically binds to somatostatin receptor 2 in vivo[1].
TATE-DA-I radiolabeled derivative [111In]In-TATE-DA-I (4.9 MBq; intravenous single injection) achieves clear visualization of SSTR2-positive neuroendocrine tumors by SPECT/CT imaging at 24 h and 48 h after injection[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
Molecular Weight 1980.00
-
Formula C87H119IN16O25S2
-
Sequence
Cyclo(Thr-Cys-Thr-Lys-{d-Trp}-Tyr-Cys)-{d-Phe}-{Tetraxetan(Bi(C2-CO))}-{γ-Lys}-{CO-C3-PhI} (Disulfide bridge:Cys2-Cys7)
-
Sequence Shortening
Cyclo(TCTK-{d-Trp}-YC)-{d-Phe}-{Tetraxetan(Bi(C2-CO))}-{γ-Lys}-{CO-C3-PhI} (Disulfide bridge:Cys2-Cys7)
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)